Search Results - "Gilham, David E."

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient by Sallman, David A, Brayer, Jason, Sagatys, Elizabeth M, Lonez, Caroline, Breman, Eytan, Agaugué, Sophie, Verma, Bikash, Gilham, David E, Lehmann, Frédéric F, Davila, Marco L

Get full text

Building better chimeric antigen receptors for adoptive T cell therapy by Bridgeman, John S, Hawkins, Robert E, Hombach, Andreas A, Abken, Hinrich, Gilham, David E

“…The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive…”
Get more information

Overcoming Target Driven Fratricide for T Cell Therapy by Breman, Eytan, Demoulin, Benjamin, Agaugué, Sophie, Mauën, Sebastien, Michaux, Alexandre, Springuel, Lorraine, Houssa, Julien, Huberty, Fanny, Jacques-Hespel, Céline, Marchand, Céline, Marijsse, Jérôme, Nguyen, Thuy, Ramelot, Nancy, Violle, Benjamin, Daro, Dorothée, De Waele, Peter, Gilham, David E, Steenwinckel, Valérie

“…Chimeric Antigen Receptor (CAR) T cells expressing the fusion of the NKG2D protein with CD3ζ (NKG2D-CAR T Cells) acquire a specificity for stress-induced…”
Get full text

Eotaxin-2 and Colorectal Cancer: A Potential Target for Immune Therapy by CHEADLE, Eleanor J, RIYAD, Kallingal, SUBAR, Daren, ROTHWELL, Dominic G, ASHTON, Garry, BATHA, Hayley, SHERLOCK, David J, HAWKINS, Robert E, GILHAM, David E

“…Purpose: To study the production of chemokines by colorectal hepatic metastases. Experimental Design: Biopsies of resected colorectal hepatic metastases and…”
Get full text

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe by Gilham, David E, Debets, Reno, Pule, Martin, Hawkins, Robert E, Abken, Hinrich

“…Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the…”
Get full text

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity by Thistlethwaite, Fiona C., Gilham, David E., Guest, Ryan D., Rothwell, Dominic G., Pillai, Manon, Burt, Deborah J., Byatte, Andrea J., Kirillova, Natalia, Valle, Juan W., Sharma, Surinder K., Chester, Kerry A., Westwood, Nigel B., Halford, Sarah E. R., Nabarro, Stephen, Wan, Susan, Austin, Eric, Hawkins, Robert E.

“…The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5 +…”
Get full text

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma by Baumeister, Susanne H, Murad, Joana, Werner, Lillian, Daley, Heather, Trebeden-Negre, Helene, Gicobi, Joanina K, Schmucker, Adam, Reder, Jake, Sentman, Charles L, Gilham, David E, Lehmann, Frédéric F, Galinsky, Ilene, DiPietro, Heidi, Cummings, Kristen, Munshi, Nikhil C, Stone, Richard M, Neuberg, Donna S, Soiffer, Robert, Dranoff, Glenn, Ritz, Jerome, Nikiforow, Sarah

“…NKG2D ligands are widely expressed in solid and hematologic malignancies but absent or poorly expressed on healthy tissues. We conducted a phase I…”
Get more information

CAR T cells: driving the road from the laboratory to the clinic by Cheadle, Eleanor J., Gornall, Hannah, Baldan, Vania, Hanson, Vivien, Hawkins, Robert E., Gilham, David E.

“…Summary Blockbuster antibody therapies have catapulted immune‐based approaches to treat cancer into the consciousness of mainstay clinical research. On the…”
Get full text

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer by Owens, Gemma L, Sheard, Victoria E, Kalaitsidou, Milena, Blount, Daniel, Lad, Yatish, Cheadle, Eleanor J, Edmondson, Richard J, Kooner, Gurdeep, Gilham, David E, Harrop, Richard

“…Chimeric antigen receptor (CAR) T cells represent a novel targeted approach to overcome both quantitative and qualitative shortfalls of the host immune system…”
Get full text

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges by Lipowska-Bhalla, Grazyna, Gilham, David E., Hawkins, Robert E., Rothwell, Dominic G.

“…The adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy…”
Get full text

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies by Springuel, Lorraine, Lonez, Caroline, Alexandre, Bertrand, Van Cutsem, Eric, Machiels, Jean-Pascal H., Van Den Eynde, Marc, Prenen, Hans, Hendlisz, Alain, Shaza, Leila, Carrasco, Javier, Canon, Jean-Luc, Opyrchal, Mateusz, Odunsi, Kunle, Rottey, Sylvie, Gilham, David E., Flament, Anne, Lehmann, Frédéric F.

“…Chimeric antigen receptor-T cells (CAR-Ts) are an exciting new cancer treatment modality exemplified by the recent regulatory approval of two CD19-targeted…”
Get full text

Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy by Michaux, Alexandre, Mauën, Sébastien, Breman, Eytan, Dheur, Marie-Sophie, Twyffels, Laure, Saerens, Laura, Jacques-Hespel, Céline, Gauthy, Emilie, Agaugué, Sophie, Gilham, David E., Sotiropoulou, Panagiota A.

“…Allogeneic chimeric antigen receptor (CAR) T holds the promise of taking this therapeutic approach to broader patient populations while avoiding the intensive…”
Get full text

The integrated stress response promotes B7H6 expression by Obiedat, Akram, Charpak-Amikam, Yoav, Tai-Schmiedel, Julie, Seidel, Einat, Mahameed, Mohamed, Avril, Tony, Stern-Ginossar, Noam, Springuel, Lorraine, Bolsée, Jennifer, Gilham, David E., Dipta, Priya, Shmuel, Miriam, Chevet, Eric, Mandelboim, Ofer, Tirosh, Boaz

“…The B7 family member, B7H6, is a ligand for the natural killer cell receptor NKp30. B7H6 is hardly expressed on normal tissues, but undergoes upregulation on…”
Get full text

Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells by Owens, Gemma L., Price, Marcus J., Cheadle, Eleanor J., Hawkins, Robert E., Gilham, David E., Edmondson, Richard J.

“…Epithelial ovarian cancer (EOC) is the leading cause of gynaecological cancer-related death in Europe. Although most patients achieve an initial complete…”
Get full text

'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors by Gilham, David E, Maher, John

“…Chimeric antigen receptor (CAR) T-cell therapy has recently been recommended for approval for certain B-cell malignancies bringing the approach closer to…”
Get full text

Exploiting natural killer group 2D receptors for CAR T-cell therapy by Demoulin, Benjamin, Cook, W. James, Murad, Joana, Graber, David J, Sentman, Marie-Louise, Lonez, Caroline, Gilham, David E, Sentman, Charles L, Agaugue, Sophie

“…Chimeric antigen receptors (CARs) are genetically engineered proteins that combine an extracellular antigen-specific recognition domain with one or several…”
Get full text

O 6-Methylguanine-DNA methyltransferase inactivation and chemotherapy by Verbeek, Barbara, Southgate, Thomas D., Gilham, David E., Margison, Geoffrey P.

“…Introduction Alkylating agents are frequently used in the chemotherapy of many types of cancer. This group of drugs mediates cell death by damaging DNA and…”
Get full text

Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival by Griffiths, Richard W, Elkord, Eyad, Gilham, David E, Ramani, Vijay, Clarke, Noel, Stern, Peter L, Hawkins, Robert E

“…Regulatory T cells are important in maintaining immune homeostasis, mediating peripheral tolerance and preventing autoimmunity. Increased frequencies of…”
Get full text

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells by Kueberuwa, Gray, Zheng, Weiming, Kalaitsidou, Milena, Gilham, David E, Hawkins, Robert E

“…The astonishing clinical success of CD19 chimeric antigen receptor (CAR) T-cell therapy has led to the approval of two second generation chimeric antigen…”
Get full text

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial by Sallman, David A, Kerre, Tessa, Havelange, Violaine, Poiré, Xavier, Lewalle, Philippe, Wang, Eunice S, Brayer, Jason B, Davila, Marco L, Moors, Ine, Machiels, Jean-Pascal, Awada, Ahmad, Alcantar-Orozco, Erik M, Borissova, Rossitza, Braun, Nathalie, Dheur, Marie-Sophie, Gilham, David E, Lonez, Caroline, Lehmann, Frédéric F, Flament, Anne

“…CYAD-01 is an autologous chimeric antigen receptor (CAR) T-cell product based on the natural killer (NK) group 2D (NKG2D) receptor, which binds eight ligands…”
Get full text